Valuation: Astellas Pharma Inc.

Market Cap 4,03000Cr 2.55TCr 2.27TCr 2.11TCr 1.92TCr 3.63TCr 2,46300Cr 3.65TCr 25TCr 9.97TCr 1,25600Cr 9.56TCr 9.35TCr P/E 2027 *
10.5x
P/E 2028 * 11x
Enterprise Value 3,97100Cr 2.51TCr 2.24TCr 2.08TCr 1.89TCr 3.58TCr 2,42700Cr 3.59TCr 25TCr 9.82TCr 1,23700Cr 9.42TCr 9.21TCr EV / Sales 2027 *
1.69x
EV / Sales 2028 * 1.61x
Free-Float
98.92%
Yield 2027 *
3.57%
Yield 2028 * 3.7%
1 day+1.13%
1 week+0.28%
Current month-0.76%
1 month-0.49%
3 months+8.87%
6 months-12.71%
Current year+8.05%
1 week 14.04
Extreme 14.04
14.59
1 month 13.92
Extreme 13.92
15.43
Current year 12.82
Extreme 12.8175
17.35
1 year 10.03
Extreme 10.03
17.35
3 years 8.37
Extreme 8.37
17.35
5 years 8.37
Extreme 8.37
18.18
10 years 8.37
Extreme 8.37
18.46
Manager TitleAgeSince
Chief Executive Officer 64 10/02/2023
Director of Finance/CFO 55 01/11/2023
Compliance Officer - 01/04/2025
Director TitleAgeSince
Chairman 66 10/02/2023
Director/Board Member 64 01/06/2019
Director/Board Member 59 01/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
+1.13%+0.28% - - 2.55TCr
+1.01%+2.88%+37.46%+105.64% 1,04300Cr
+1.70%+1.83%+36.45%+64.45% 62TCr
-0.40%+5.06%+19.69%+85.17% 48TCr
+2.51%+1.20%+66.89%+39.74% 35TCr
+1.45%+2.52%+22.83%+44.22% 34TCr
+1.17%+0.88%+11.83%+34.76% 27TCr
+0.89%+1.08%-7.28%+10.52% 24TCr
+1.80%+3.30%+40.93%+53.33% 22TCr
+2.77%+4.36%+29.39%+101.24% 18TCr
Average +1.55%+0.28%+28.69%+59.90% 41.63TCr
Weighted average by Cap. +1.37%+0.60%+31.51%+69.93%

Financials

2027 *2028 *
Net sales 2,35500Cr 1.49TCr 1.33TCr 1.24TCr 1.12TCr 2.12TCr 1,44000Cr 2.13TCr 15TCr 5.83TCr 73TCr 5.59TCr 5.46TCr 2,20000Cr 1.39TCr 1.24TCr 1.15TCr 1.05TCr 1.98TCr 1,34500Cr 1.99TCr 14TCr 5.44TCr 69TCr 5.22TCr 5.1TCr
Net income 37TCr 233.53Cr 208.56Cr 194.02Cr 176.47Cr 333.21Cr 23TCr 334.65Cr 2.34TCr 914.94Cr 12TCr 876.95Cr 857.77Cr 35TCr 220.11Cr 196.58Cr 182.87Cr 166.34Cr 314.06Cr 21TCr 315.42Cr 2.2TCr 862.37Cr 11TCr 826.56Cr 808.49Cr
Net Debt -5.92TCr -37Cr -33Cr -31Cr -28Cr -53Cr -3.62TCr -54Cr -373.71Cr -146.43Cr -1.84TCr -140.35Cr -137.28Cr -48TCr -303.56Cr -271.11Cr -252.2Cr -229.39Cr -433.12Cr -29TCr -435Cr -3.04TCr -1.19TCr -15TCr -1.14TCr -1.11TCr
Projected Income Statement - Annual - Astellas Pharma Inc.
Logo Astellas Pharma Inc.
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Employees
14,099
Date Price Change Volume
10/26/10 $14.35 +1.06% 1,22,213
08/26/08 $14.20 -0.28% 95,020
07/26/07 $14.24 +0.64% 1,07,593
06/26/06 $14.15 -0.42% 1,01,048
05/26/05 $14.21 -0.77% 97,181
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Astellas Pharma Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
2,247.50JPY
Average target price
2,529.29JPY
Spread / Average Target
+12.54%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Astellas Pharma Inc.